Pancreatic Cancer: Basic Mechanisms and Therapies (inbunden, eng)
Gäller medlemspriset
Pancreatic Cancer: Basic Mechanisms and Therapies (inbunden, eng)
Gästpris:
Ditt pris:
1 581 kr
1 769 kr
Kampanjpris!
- Inköpspriser för medlemmar (Logga in)
- Frakt från 0 kr
- 14 dagars öppet köp
Pancreatic Cancer: Basic Mechanisms and Therapies, Volume 159 in the Advances in Cancer Research, presents the latest release in this ongoing, well-regarded serial with invaluable information on the exciting and fast-moving field of cancer research. Pancreatic cancer (PC) is the third leading cause of cancer-related deaths in the United States.
Greater than 90% PCs are Pancreatic ductal adenocarcinomas (PDAC) which have a dismal estimated 5-year overall survival of only 11%. PDAC is predicted to become the second leading cause of mortality in the United States by 2030. In the clinic, the PDAC patients often present with incurable disease at the time of first diagnosis.
This cancer is particularly lethal because of its propensity to spread quickly to distant organs including the lymphatic system. PDAC metastasis occurs shortly after tumor initiation and is caused by a complex interaction between autonomous tumor cells and cellular elements of the tumor microenvironment.
Although PDAC remains a challenging disease to treat and a leading cause of cancer-related deaths, progress is being made in disease etiology and pathogenesis, and intensive research is focused on developing optimal treatment approaches for patients. Considering the continuous progress being made in understanding PDAC pathogenesis and designing new therapies, it was considered timely to develop an up-to-date thematic issue of Advances in Cancer Research (ACR) focused on PDAC.
In this thematic issue, we have included ten review articles by experts that cover cancer disparities, PDAC pathobiology, the roles of the tumor microenvironment, tumor heterogeneity, PC stem cells, genetic and signaling events critical for PDAC pathogenesis, Immunotherapy and chemoresistance in PDAC, and different PDAC mouse models.
This special issue highlights recent research progress in PDAC, which bridges the gap between basic and clinical research.
Greater than 90% PCs are Pancreatic ductal adenocarcinomas (PDAC) which have a dismal estimated 5-year overall survival of only 11%. PDAC is predicted to become the second leading cause of mortality in the United States by 2030. In the clinic, the PDAC patients often present with incurable disease at the time of first diagnosis.
This cancer is particularly lethal because of its propensity to spread quickly to distant organs including the lymphatic system. PDAC metastasis occurs shortly after tumor initiation and is caused by a complex interaction between autonomous tumor cells and cellular elements of the tumor microenvironment.
Although PDAC remains a challenging disease to treat and a leading cause of cancer-related deaths, progress is being made in disease etiology and pathogenesis, and intensive research is focused on developing optimal treatment approaches for patients. Considering the continuous progress being made in understanding PDAC pathogenesis and designing new therapies, it was considered timely to develop an up-to-date thematic issue of Advances in Cancer Research (ACR) focused on PDAC.
In this thematic issue, we have included ten review articles by experts that cover cancer disparities, PDAC pathobiology, the roles of the tumor microenvironment, tumor heterogeneity, PC stem cells, genetic and signaling events critical for PDAC pathogenesis, Immunotherapy and chemoresistance in PDAC, and different PDAC mouse models.
This special issue highlights recent research progress in PDAC, which bridges the gap between basic and clinical research.
| Format | Inbunden |
| Omfång | 390 sidor |
| Språk | Engelska |
| Förlag | Elsevier Science Publishing Co Inc |
| Utgivningsdatum | 2023-06-01 |
| ISBN | 9780443133541 |
Artikelnummer
3194487
EAN
9780443133541
Leverans:
Denna produkt skickas från oss inom 4 - 5 vardagar. I kassan väljer du om du vill få leverans med Budbee, Airmee, Best Transport, Early Bird, Postnord eller DB Schenker. Vissa speditörer har vikt- eller storleksbegränsningar och kan av den anledningen saknas som alternativ i kassan om du handlar många eller väldigt stora produkter.Fri retur:
För Plus-medlemmar gäller fri retur och 14 dagars full returrätt från den dagen du tar emot din leverans. För övriga kostar retur från 49 kr.Undantag för retur- och ångerrätt:
Dessa är exempel på varor som inte omfattas av retur- eller ångerrätt. Observera att det kan finnas andra undantag som inte listas här.- Använda, skadade och/eller inkompletta produkter
- Dagligvaror (livsmedel, läkemedel, nikotinprodukter)
- Hygienartiklar & kroppsnära produkter (rakapparater, in ear-hörlurar, aktivitetsklockor)
- Intimprodukter (menskoppar, kondomer och glidmedel)
- Kosmetikprodukter (inkl. hår- och hudvårdsprodukter, parfymer, etc.)
- Underkläder (inkl. badkläder, underställ och strumpor)
- Ljud- & bildupptagningar, spel/program (om förseglingen brutits eller licensnyckeln erhållits.)
- Teknikprodukter om försegling brutits eller programvara har installerats (mobiltelefoner, surfplattor, laptops, etc.)
- Gratisprodukter
Om du är osäker på om en produkt omfattas av ångerrätt kan du alltid kontakta vår kundtjänst på info@buyersclub.se, så hjälper vi dig gärna!
Leveranser:
